An observational study in Cancer Patients With Solid Tumors and Cancer (Advanced Stage), sponsored by China Medical University Hospital. Active, not recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by China Medical University Hospital · Observational
The goal of this clinical trial is to learn whether a new laboratory method called OPTin can help doctors select the most effective, personalized cancer therapies for patients with advanced or treatment-resistant tumors. The study will also learn about the safety and feasibility of using OPTin to guide treatment decisions across different cancer types.
The main questions it aims to answer are:
Does OPTin accurately identify which drugs or drug combinations work best for each patient's tumor?
Does OPTin-guided therapy improve tumor response or remission rates when the patients don't have any standard treatment selection?
Study Design:
Researchers will collect treatment outcomes in patients whose therapy is chosen based on OPTin results or not in cancer patients without standard treatment.
Participants will:
Provide a small tumor tissue sample for OPTin testing.
Receive either a drug or drug combination identified by OPTin, or a physician's decision treatment.
Visit the clinic regularly for imaging, blood tests, and side-effect monitoring.
Be followed for several months to evaluate treatment response and overall health.
Example Case:
In a previous proof-of-concept study, OPTin screening in a patient with advanced hypopharyngeal carcinoma identified venetoclax as effective for the primary tumor and lenvatinib as a sensitizing agent for metastasis. Combination therapy led to near-complete remission and a significant drop in serum AFP levels.
These results support evaluating OPTin in a prospective clinical trial involving diverse cancer types to confirm its usefulness in guiding precision oncology.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 200 is close to the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The patients will receive treatments in CMUH.
Exclusion Criteria:
a screening system that integrates organotypic tissue slice cultures, optical clearing, and high-resolution fluorescence imaging.
response rate
Time frame: through study completion, an average of 1 year"
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes
Supporting information: Study protocol, Icf
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital